269 related articles for article (PubMed ID: 9124242)
1. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I.
Friedlaender MH; Howes J
Am J Ophthalmol; 1997 Apr; 123(4):455-64. PubMed ID: 9124242
[TBL] [Abstract][Full Text] [Related]
2. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis.
Asbell P; Howes J
CLAO J; 1997 Jan; 23(1):31-6. PubMed ID: 9001768
[TBL] [Abstract][Full Text] [Related]
3. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group.
Dell SJ; Shulman DG; Lowry GM; Howes J
Am J Ophthalmol; 1997 Jun; 123(6):791-7. PubMed ID: 9535623
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis.
Bartlett JD; Howes JF; Ghormley NR; Amos JF; Laibovitz R; Horwitz B
Curr Eye Res; 1993 Apr; 12(4):313-21. PubMed ID: 8319490
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis.
Dell SJ; Lowry GM; Northcutt JA; Howes J; Novack GD; Hart K
J Allergy Clin Immunol; 1998 Aug; 102(2):251-5. PubMed ID: 9723669
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model.
Berdy GJ; Stoppel JO; Epstein AB
Clin Ther; 2002 Jun; 24(6):918-29. PubMed ID: 12117082
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis.
Shulman DG; Lothringer LL; Rubin JM; Briggs RB; Howes J; Novack GD; Hart K
Ophthalmology; 1999 Feb; 106(2):362-9. PubMed ID: 9951491
[TBL] [Abstract][Full Text] [Related]
8. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate.
Abelson M; Howes J; George M
J Ocul Pharmacol Ther; 1998 Dec; 14(6):533-42. PubMed ID: 9867336
[TBL] [Abstract][Full Text] [Related]
9. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group.
Am J Ophthalmol; 1999 May; 127(5):537-44. PubMed ID: 10334346
[TBL] [Abstract][Full Text] [Related]
10. Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1.
Stewart R; Horwitz B; Howes J; Novack GD; Hart K
J Cataract Refract Surg; 1998 Nov; 24(11):1480-9. PubMed ID: 9818338
[TBL] [Abstract][Full Text] [Related]
11. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. The Loteprednol Etabonate Postoperative Inflammation Study Group 2.
Ophthalmology; 1998 Sep; 105(9):1780-6. PubMed ID: 9754192
[TBL] [Abstract][Full Text] [Related]
12. Change in intraocular pressure during long-term use of loteprednol etabonate.
Novack GD; Howes J; Crockett RS; Sherwood MB
J Glaucoma; 1998 Aug; 7(4):266-9. PubMed ID: 9713785
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis.
Ilyas H; Slonim CB; Braswell GR; Favetta JR; Schulman M
Eye Contact Lens; 2004 Jan; 30(1):10-3. PubMed ID: 14722462
[TBL] [Abstract][Full Text] [Related]
14. Loteprednol etabonate: clinical potential in the management of ocular inflammation.
Noble S; Goa KL
BioDrugs; 1998 Oct; 10(4):329-39. PubMed ID: 18020605
[TBL] [Abstract][Full Text] [Related]
15. Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients.
Gong L; Sun X; Qu J; Wang L; Zhang M; Zhang H; Wang L; Gu Y; Elion-Mboussa A; Roy L; Zhu B
Clin Ther; 2012 Jun; 34(6):1259-1272.e1. PubMed ID: 22627057
[TBL] [Abstract][Full Text] [Related]
16. Intraocular pressure elevations with loteprednol etabonate: a retrospective chart review.
Rajpal RK; Digby D; D'Aversa G; Mah F; Hollander DA; Conway T
J Ocul Pharmacol Ther; 2011 Jun; 27(3):305-8. PubMed ID: 21574815
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects.
Comstock TL; Paterno MR; Bateman KM; Decory HH; Gearinger M
Paediatr Drugs; 2012 Apr; 14(2):119-30. PubMed ID: 22292487
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance.
Pflugfelder SC; Maskin SL; Anderson B; Chodosh J; Holland EJ; De Paiva CS; Bartels SP; Micuda T; Proskin HM; Vogel R
Am J Ophthalmol; 2004 Sep; 138(3):444-57. PubMed ID: 15364229
[TBL] [Abstract][Full Text] [Related]
19. Comparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: prospective randomized double-masked study.
Holzer MP; Solomon KD; Sandoval HP; Vroman DT
J Cataract Refract Surg; 2002 Jan; 28(1):93-9. PubMed ID: 11777716
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery.
Rajpal RK; Roel L; Siou-Mermet R; Erb T
J Cataract Refract Surg; 2013 Feb; 39(2):158-67. PubMed ID: 23218817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]